Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15157018 | 0.84 | DAO (0.49) | MEN1KMT2ADAOALDH1A1KDM4E | |
| SCHEMBL9981108 | 0.81 | DAO (0.58) | KMT2ADAOALDH1A1KDM4EHPGD | |
| SCHEMBL2247787 | 0.80 | DAO (0.54) | MEN1KMT2ADAOALDH1A1KDM4E | |
| SCHEMBL9535451 | 0.80 | MEN1 (0.59) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL13332558 | 0.79 | CYP1A2 (0.62) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL24312042 | 0.79 | DAO (0.58) | MEN1KMT2ADAOALDH1A1KDM4E | |
| SCHEMBL1294865 | 0.79 | DAO (0.47) | MEN1KMT2ADAOALDH1A1MAPT | |
| SCHEMBL30891925 | 0.79 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL9139429 | 0.79 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL3120343 | 0.78 | JAK2 (0.43) | MEN1KMT2AALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585462-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-02-26 | — | — | EP | disclosed |
| CN-103153995-B | Condensed heterocyclic compouds as phosphodiesterase (PDES) inhibitor | 武田药品工业株式会社 | 2016-08-10 | — | — | CN | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| CN-103153995-A | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL | 2013-06-12 | — | — | CN | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110190336-A1 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190336-A1 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010045276-A2 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045276-A2 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | MEN1 3708/4885KMT2A 2378/4885DAO 345/4885 |
| US-20110190336-A1 | AZABENZIMIDAZOLONES | PTGER1, PTGDR, PTGER2 | MEN1 4553/4885KMT2A 3431/4885DAO 2104/4885 |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | MEN1 3479/4885KMT2A 871/4885DAO 665/4885 |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | MEN1 3479/4885KMT2A 871/4885DAO 665/4885 |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | MEN1 3708/4885KMT2A 2378/4885DAO 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.